Prediction of Visual Acuity in Patients With Microbial Keratitis.
Prediction of Visual Acuity in Patients With Microbial Keratitis.
复制标题
微生物性角膜炎患者视力的预测。
DOI:
10.1097/ico.0000000000003129
复制
发表时间:
2023
期刊:
影响因子:
2.8
通讯作者:
Singh,Karandeep
中科院分区:
文献类型:
--
作者:
Woodward,MariaA;Niziol,LeslieM;Ballouz,Dena;Lu,Ming-Chen;Kang,Linda;Thibodeau,Alexa;Singh,Karandeep
Purpose:The purpose of this study was to predict visual acuity (VA) 90 days after presentation for patients with microbial keratitis (MK) from data at the initial clinical ophthalmic encounter.Methods:Patients with MK were identified in the electronic health record between August 2012 and February 2021. Random forest (RF) models were used to predict 90-day VA< 20/40 [visual impairment (VI)]. Predictors evaluated included age, sex, initial VA, and information documented in notes at presentation. Model diagnostics are reported with 95% confidence intervals (CIs) for area under the curve (AUC), misclassification rate, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).Results:One thousand seven hundred ninety-one patients were identified. The presenting logMAR VA was on average 0.86 (Snellen equivalent and standard deviation= 20/144±12.6 lines) in the affected or worse eye, and 43.6% with VI. VI at 90-day follow-up was present in the affected eye or worse eye for 26.9% of patients. The RF model for predicting 90-day VI had an AUC of 95%(CI: 93%–97%) and a misclassification rate of 9%(7%–12%). The percent sensitivity, specificity, PPV, and NPV were 86%(80%–91%), 92%(89%–95%), 81%(74%–86%), and 95%(92%–97%), respectively. Older age, worse presenting VA, and more mentions of “penetrating keratoplasty” and “bandage contact lens” were associated with increased probability of 90-day VI, whereas more mentions of “quiet” were associated with decreased probability of 90-day VI.Conclusions:RF modeling yielded good sensitivity and specificity to predict VI at 90 days which could guide clinicians about the risk of poor vision outcomes for patients with MK.